LLY

744.38

-1.95%↓

JNJ

154.8

-0.78%↓

UNH

380.03

-1.9%↓

ABBV

186.95

+0.65%↑

ABT

134.06

-0.45%↓

LLY

744.38

-1.95%↓

JNJ

154.8

-0.78%↓

UNH

380.03

-1.9%↓

ABBV

186.95

+0.65%↑

ABT

134.06

-0.45%↓

LLY

744.38

-1.95%↓

JNJ

154.8

-0.78%↓

UNH

380.03

-1.9%↓

ABBV

186.95

+0.65%↑

ABT

134.06

-0.45%↓

LLY

744.38

-1.95%↓

JNJ

154.8

-0.78%↓

UNH

380.03

-1.9%↓

ABBV

186.95

+0.65%↑

ABT

134.06

-0.45%↓

LLY

744.38

-1.95%↓

JNJ

154.8

-0.78%↓

UNH

380.03

-1.9%↓

ABBV

186.95

+0.65%↑

ABT

134.06

-0.45%↓

Search

Lyell Immunopharma Inc

Chiusa

0.42 2.44

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.4

Massimo

0.43

Metriche Chiave

By Trading Economics

Entrata

-147M

-192M

Vendite

-23K

11K

EPS

-0.172

Margine di Profitto

-1,744,863.636

Dipendenti

300

EBITDA

-12M

-58M

Raccomandazioni

By TipRanks

Raccomandazioni

Vendi

Previsioni per 12 mesi

+138.1% upside

Dividendi

By Dow Jones

Utili prossimi

12 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-88M

128M

Apertura precedente

-2.02

Chiusura precedente

0.42

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Lyell Immunopharma Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 mag 2025, 23:59 UTC

Notizie principali
Utili

Naver 1Q Net Slumps on Higher Costs

8 mag 2025, 23:39 UTC

Utili

OCBC 1Q Net Down on Lower Interest Income

8 mag 2025, 23:01 UTC

Utili

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 mag 2025, 22:52 UTC

Utili

REA Expects Annual Listings Growth Despite April Decline

8 mag 2025, 22:46 UTC

Utili

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 mag 2025, 23:45 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 mag 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 mag 2025, 23:41 UTC

Discorsi di Mercato

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 mag 2025, 23:30 UTC

Utili

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 mag 2025, 23:29 UTC

Utili

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 mag 2025, 23:22 UTC

Utili

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 mag 2025, 23:22 UTC

Utili

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 mag 2025, 23:21 UTC

Utili

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 mag 2025, 23:21 UTC

Utili

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 mag 2025, 23:17 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 mag 2025, 23:17 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 mag 2025, 23:17 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 mag 2025, 23:05 UTC

Discorsi di Mercato

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 mag 2025, 23:05 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 mag 2025, 23:01 UTC

Notizie principali

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 mag 2025, 22:28 UTC

Utili

REA Expects FY 2025 Listings Growth of 1-2%

8 mag 2025, 22:28 UTC

Utili

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 mag 2025, 22:27 UTC

Utili

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 mag 2025, 22:27 UTC

Utili

REA Says April Residential Listings Fell by 11% on Year

8 mag 2025, 22:26 UTC

Utili

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 mag 2025, 22:26 UTC

Utili

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 mag 2025, 22:26 UTC

Utili

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 mag 2025, 22:26 UTC

Utili

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 mag 2025, 22:25 UTC

Utili

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 mag 2025, 22:25 UTC

Utili

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Confronto tra pari

Modifica del prezzo

Lyell Immunopharma Inc Previsione

Obiettivo di Prezzo

By TipRanks

138.1% in crescita

Previsioni per 12 mesi

Media 1 USD  138.1%

Alto 1 USD

Basso 1 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lyell Immunopharma Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Vendi

2 ratings

0

Acquista

1

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

0.407 / 0.4691Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.